miR-498/DNMT3b Axis Mediates Resistance to Radiotherapy in Esophageal Cancer Cells

Weihe Zhou1, Haoqi Zhu2, Yuan Xu2

  • 1Department of Cardiothoracic Surgery and the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, P.R. China.

Insights

MicroRNA-498 (miR-498) enhances esophageal cancer radiosensitivity by inhibiting DNMT3b, thereby inactivating the PI3K/AKT pathway. This finding offers a potential therapeutic target for overcoming radiotherapy resistance in esophageal cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Esophageal cancer (EC) frequently develops resistance to radiotherapy.
  • Understanding the molecular mechanisms underlying radioresistance is crucial for improving treatment outcomes.

Purpose of the Study:

  • To investigate the role of miR-498 in esophageal cancer radiotherapy resistance.
  • To elucidate the underlying molecular mechanism involving DNMT3b and the PI3K/AKT pathway.

Main Methods:

  • Analysis of miR-498 and DNMT3b expression in patient-derived radioresistant/radiosensitive EC tissues.
  • In vitro studies using KYSE30 cells involving gene overexpression/knockdown and irradiation.
  • Assessment of cell viability, colony formation, apoptosis, and Western blot analysis of signaling pathway proteins (PI3K/AKT).

Main Results:

  • Lower miR-498 and higher DNMT3b expression were observed in radioresistant EC tissues compared to radiosensitive ones.
  • Overexpression of miR-498 or knockdown of DNMT3b significantly increased EC cell radiosensitivity.
  • DNMT3b was identified as a direct target of miR-498, and its inhibition by miR-498 led to the inactivation of the PI3K/AKT signaling pathway.

Conclusions:

  • MiR-498 functions as a tumor suppressor in esophageal cancer radiotherapy resistance.
  • MiR-498 enhances radiosensitivity by targeting DNMT3b and inhibiting the PI3K/AKT pathway.
  • Targeting the miR-498/DNMT3b axis presents a potential therapeutic strategy for overcoming EC radioresistance.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.3K